ArticleCell2022
Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope.
Open access · hybridAbstract read
In one paragraph
Article in Cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.
0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed
10.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 103 citations in OpenAlex.
- Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients.Haematologica · 2023Trial
- gAIRR-wgs: high-resolution T cell receptor allele typing in biobank-scale whole-genome sequencing data.Briefings in bioinformatics · 2026Article
- Distinct CD8iScience · 2026Article
- Position-5-driven reorientation of an immunodominant HLA-A*24:02 SARS-CoV-2 epitope drives universal T cell escape.JCI insight · 2026Article
- SwiftTCR: efficient computational docking protocol of TCRpMHC-I complexes using restricted rotation matrices.Briefings in bioinformatics · 2026Article
- SARS-CoV-2 Variants and Immune Evasion: Mapping the Future of Vaccine Design.Reviews in medical virology · 2026Review
- Extensive evolution and T cell escape by SARS-CoV-2 in a 2.5-year persistent infection of an immunocompromised host.iScience · 2026Article
- Vaccination-driven evolution of infectious bronchitis virus in Korea: implication for the control of other coronavirus infections.Frontiers in veterinary science · 2026Review
- Viral diversity influences T-cell responses to enteric human adenoviruses F40 and F41.Virus evolution · 2026Article
- Resistance potential of the HLA-A2-restricted immunodominant SARS-CoV-2-specific CD8Nature communications · 2025Article
- Structural insights into clonal restriction and diversity in T cell recognition of two immunodominant SARS-CoV-2 nucleocapsid epitopes.Nature communications · 2025Article
- Molecular basis of potent antiviral HLA-C-restricted CD8Nature communications · 2025Article
- Exploring the oncogenic potential of SARS-CoV-2 in the gastrointestinal tract.World journal of gastroenterology · 2025Review
- Identification of immune signatures associated with both SARS-CoV-2 infection and lung transplantation.Cell reports. Medicine · 2025Article
- T cell epitope mapping reveals immunodominance of evolutionarily conserved regions within SARS-CoV-2 proteome.iScience · 2025Article
- Analysis of Hyperexpanded T Cell Clones in SARS-CoV-2 Vaccine-Associated Liver Injury by Spatial Proteomics and Transcriptomics.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- A naturally selected αβ T cell receptor binds HLA-DQ2 molecules without co-contacting the presented peptide.Nature communications · 2025Article
- SARS-CoV-2: The Interplay Between Evolution and Host Immunity.Annual review of immunology · 2025Review
- The Impact of Vaccination Frequency on COVID-19 Public Health Outcomes: A Model-Based Analysis.Vaccines · 2025Article
- APMAT analysis reveals the association between CD8 T cell receptors, cognate antigen, and T cell phenotype and persistence.Nature communications · 2025Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 4 institutions in 1 country.
Garry DoltonDivision of Infection and Immunity, Cardiff University School of Medicine, CF14 4XN Cardiff, Wales, UK.
Cristina RiusDivision of Infection and Immunity, Cardiff University School of Medicine, CF14 4XN Cardiff, Wales, UK.
Md Samiul HasanDivision of Infection and Immunity, Cardiff University School of Medicine, CF14 4XN Cardiff, Wales, UK.
Aaron WallDivision of Infection and Immunity, Cardiff University School of Medicine, CF14 4XN Cardiff, Wales, UK.
Barbara SzomolayDivision of Infection and Immunity, Cardiff University School of Medicine, CF14 4XN Cardiff, Wales, UK; Systems Immunology Research Institute, Cardiff University, CF14 4XN Cardiff, Wales, UK.
Enas BehiryDivision of Infection and Immunity, Cardiff University School of Medicine, CF14 4XN Cardiff, Wales, UK.
Thomas WhalleySchool of Biosciences, Cardiff University, CF10 3AX Cardiff, Wales, UK.
Joel SouthgateSchool of Biosciences, Cardiff University, CF10 3AX Cardiff, Wales, UK.
Anna FullerDivision of Infection and Immunity, Cardiff University School of Medicine, CF14 4XN Cardiff, Wales, UK.
COVID-19 Genomics UK (COG-UK) consortium
Théo MorinDivision of Infection and Immunity, Cardiff University School of Medicine, CF14 4XN Cardiff, Wales, UK.
Katie TopleyDivision of Infection and Immunity, Cardiff University School of Medicine, CF14 4XN Cardiff, Wales, UK.
Li Rong TanDivision of Infection and Immunity, Cardiff University School of Medicine, CF14 4XN Cardiff, Wales, UK.
Philip J R GoulderDepartment of Paediatrics, University of Oxford, OX3 9DU Oxford, England, UK.
Owen B SpillerDivision of Infection and Immunity, Cardiff University School of Medicine, CF14 4XN Cardiff, Wales, UK.
Pierre J RizkallahDivision of Infection and Immunity, Cardiff University School of Medicine, CF14 4XN Cardiff, Wales, UK.
Lucy C JonesDivision of Infection and Immunity, Cardiff University School of Medicine, CF14 4XN Cardiff, Wales, UK; Centre for Clinical Research, Royal Glamorgan Hospital, Ynysmaerdy CF72 8XR, UK.
Thomas R ConnorSystems Immunology Research Institute, Cardiff University, CF14 4XN Cardiff, Wales, UK; School of Biosciences, Cardiff University, CF10 3AX Cardiff, Wales, UK; Pathogen genomics Unit, Public Health Wales NHS Trust, CF14 4XW Cardiff, Wales, UK. Electronic address: connortr@cardiff.ac.uk.
Andrew K SewellDivision of Infection and Immunity, Cardiff University School of Medicine, CF14 4XN Cardiff, Wales, UK; Systems Immunology Research Institute, Cardiff University, CF14 4XN Cardiff, Wales, UK. Electronic address: sewellak@cardiff.ac.uk.
Cardiff University · GBPublic Health Wales · GBUniversity Hospital of Wales · GBUniversity of Oxford · GB
Funding
Medical Research Council MC_PC_19027Medical Research Council MR/L015080/1Wellcome Trust
Abstract
We studied the prevalent cytotoxic CD8 T cell response mounted against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoprotein
Indexed as
COVID-19SARS-CoV-2CD8-Positive T-LymphocytesEpitopes, T-LymphocyteHistocompatibility Antigens Class IHLA-A AntigensHumansEpitopes, T-LymphocyteHistocompatibility Antigens Class IHLA-A AntigensCD8 T cellCOVID-19immune escapepeptide-HLAphylogeneticSARS-CoV-2T cellT cell receptors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.